Radiation Therapy 👉 Analysis

The bridge

The Modalities page describes the radiation family in general — EBRT, brachytherapy, SBRT, ADT — and what recovery looks like. This page reads those same modalities through my biopsy findings. Same options, sharper questions: which modality actually fits, whether ADT is on the table, what the cribriform / IDC-P findings mean for radiation specifically, and what radiation would not answer that surgery would.

The findings that shape the radiation conversation

From the May 18 pathology plus the April 22 MRI:

• Grade Group 2 (Gleason 3+4=7). The starting point for risk classification.
• Intraductal carcinoma (IDC-P) in one sample. Adverse feature.
• Cribriform pattern in two samples. Adverse feature.
• 3 of 13 specimen containers positive, all right-sided. Right mid PZPL and right lateral.
• MRI on the right mid PZPL lesion: “No definite EPE but broad abutment on capsule.” No visible extension on imaging, but a wide line of contact with the capsule that's the typical signature for microscopic EPE. MSK's June re-read confirmed the same staging picture — contained, mild capsular bulge, no clear break.
• New on the left: MSK's June MRI re-read flagged a small, lower-suspicion spot on the left (PI-RADS 4, ~0.8 cm) and the PSMA PET lit it faintly — a possible second cancer or just inflammation, still unconfirmed, with an open question about the base of the left seminal vesicle. If real, it could widen the radiation field or shift the boost.

Risk classification — this is what radiation strategy keys off

Radiation decisions are driven less by Grade Group alone and more by where the case falls in the NCCN risk groups. Grade Group 2 with adverse pathology features (cribriform + IDC-P) sits right on the favorable/unfavorable intermediate boundary — and my doctors don't fully agree which side it lands on. Most read it as favorable intermediate; MSK grades it one notch higher, at unfavorable intermediate, on the strength of those adverse features. That disagreement isn't academic: it's the lever for whether ADT gets added.

That classification is the lever for two big radiation decisions: which modality, and whether ADT is added.

Which modality fits

For intermediate-risk disease with capsular abutment and adverse features, the realistic candidates narrow:

When I consulted them, both radiation oncologists proposed short-course radiation — Dr. Setton (MSK) a standard short course, Dr. Lipsztein (Northwell) a short course with an extra dose aimed at the tumor (a boost). The exact modality and fractionation are part of the detailed plan still to come.

The ADT question

At unfavorable intermediate risk, NCCN guidelines support adding short-course androgen deprivation therapy — typically 4–6 months — to radiation, with multiple randomized trials showing a survival benefit in that band. But whether I land there is exactly the contested question above. Dr. Setton would add ADT only if the pending tests bump my risk upward; Dr. Lipsztein left it as a possibility. So the genomic results, not a settled risk grade, decide whether hormone therapy is part of the radiation plan.

What that means concretely: hot flashes, fatigue, libido loss, ED layered on top of radiation's own ED curve, muscle and bone-density loss, mood and metabolic shifts. Most reverse within a year of stopping, but recovery is age-sensitive and gets slower the longer the course. At 66, a 4–6 month course is recoverable; it is not nothing.

This is the hidden cost on the radiation side. The surgery side asks “will the right neurovascular bundle survive?” The radiation side asks “am I willing to do six months on ADT?” Both questions matter to quality of life and they are not the same question.

The cribriform / IDC-P question

Cribriform pattern and intraductal carcinoma both predict more aggressive behavior than the Grade Group number alone suggests. The open clinical question is whether they're also relatively radioresistant — whether radiation works as well against these patterns as it does against ordinary acinar Gleason pattern 4.

Published evidence here is genuinely mixed. Some retrospective series show worse biochemical control after radiation in cribriform-predominant disease; others find comparable outcomes when ADT and adequate dose are used. Neither pattern rules radiation out, and no major guideline does. But it's a question worth raising directly with the radiation oncologist and the surgeon both: do these patterns change the case for one path over the other?

Genomic testing (Decipher and Artera) is the tool most likely to refine this — and with the PET now done, it's the last input I'm waiting on. A high Decipher score can shift the recommendation toward more aggressive treatment, longer ADT, or surgery; a low score in cribriform disease can pull the recommendation in the other direction.

What radiation doesn't settle that surgery would

This is the asymmetry that runs in surgery's favor on data clarity:

• No surgical pathology. No full-gland section. The true grade, the definitive EPE answer, the margin status, the seminal vesicle assessment, and the lymph-node status all remain inferred rather than confirmed.
• PSA-driven monitoring only. PSA falls to a nadir over a year; biochemical recurrence is defined as PSA rising 2 ng/mL above that nadir. The signal lags the disease.
• The “broad capsular abutment” question stays a probability. With radiation, the EPE question is never definitively answered. The radiation field covers it; nothing tells you whether it was there.

Salvage considerations — which way the door swings

If treatment fails (PSA rises after a period of control), the available next steps depend on which path was taken first:

• If radiation fails first: salvage prostatectomy is technically possible but harder — scarred tissue planes, worse continence and erectile outcomes, higher complication rate. Salvage radiation (a second course to the same area) is generally not possible. ADT and focal treatments become the main responses.
• If surgery fails first: salvage radiation is well-established and effective. The prostate bed gets radiated, often with ADT.

This is one of the few asymmetries between the paths that isn't really about side effects. Doing surgery first preserves radiation as a salvage tool. Doing radiation first largely closes the surgical door.